Theophylline
- Generic Name
- Theophylline
- Brand Names
- Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8N4O2
- CAS Number
- 58-55-9
- Unique Ingredient Identifier
- 0I55128JYK
- Background
A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
- Indication
For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation
A Study of LY2216684 and Theophylline in Healthy Subjects
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01263106
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
Theophylline in Rhinitis
- Conditions
- AsthmaRhinosinusitisAllergic Rhinitis
- Interventions
- Drug: Placebo (Placebo Group)
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- University of East Anglia
- Target Recruit Count
- 28
- Registration Number
- NCT01132781
- Locations
- 🇬🇧
University of East Anglia, Norwich, Norfolk, United Kingdom
CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2010-03-03
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 87
- Registration Number
- NCT01066728
- Locations
- 🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦St Boniface General Hospital, Winnipeg, Manitoba, Canada
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Neoplasms
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01017939
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Drug-Drug Interaction Study of Colchicine and Theophylline
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00983905
- Locations
- 🇺🇸
PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota, United States
The Effect on Small Airways of Addition of Theophylline as Inducer of Histone Deacilase Activity for Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Treated With Inhaled Steroids and Long Acting Beta Agonists
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00893009
- Locations
- 🇮🇱
Pulmonar Institute, Assaf Harofeh Medical Center, Beer Yaakov, Israel
Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2009-10-28
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00779259
- Locations
- 🇺🇸
PRACS Institute, Fargo, North Dakota, United States
Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 84
- Registration Number
- NCT00756418
Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Hospital Universitari Son Dureta
- Target Recruit Count
- 35
- Registration Number
- NCT00671151
- Locations
- 🇪🇸
Hospital Universitario Son Dureta, Palma de Mallorca, Baleares, Spain
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- Pulmagen Therapeutics
- Target Recruit Count
- 91
- Registration Number
- NCT00634413
- Locations
- 🇵🇱
Jagiellonian University of Medicine, Krakow, Poland
🇬🇧The London Chest Hospital, London, United Kingdom
🇬🇧Glenfield Hospital, Leicester, Leicestershire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.